Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 30Terminated 6Unknown 3Withdrawn 2Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

pembrolizumab 198Nivolumab 146Carboplatin 133Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 112Paclitaxel 106Biopsy 97Cisplatin 94Radiotherapy 89durvalumab 83Dexamethasone 80atezolizumab 73Ipilimumab 66Gemcitabine 60Doxorubicin 60Rituximab 59Lenalidomide 56Docetaxel 55olaparib 51Etoposide 51Bevacizumab 51Fluorouracil 49Capecitabine 49Radiation 47Oxaliplatin 47Radiosurgery 43Prednisone 43venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × plerixafor × Clear all
NCT02570542 2025-11-26

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
59 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡